Insights into the Design of MYC-Targeting Proteolysis Targeting Chimeras (PROTACs)
Molecules · 2026
DOI: 10.3390/molecules31061011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2026. Verfasst von Abdallah M Alfayomy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Institute of Pharmacy, Martin-Luther-University of Halle-Wittenberg, 06120 Halle (Saale), Germany. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-myc. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation DFG, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
The oncogenic transcription factor MYC is a key driver of the development and progression of various types of cancer, but its intrinsically disordered structure and dependence on protein–protein interactions make it a difficult therapeutic target. Proteolysis-targeting chimeras (PROTACs) are bifunctional molecules that can induce the selective degradation of disease-relevant proteins. In this study, we report the synthesis and biological testing of a series of novel MYC-targeted PROTACs derived from the MYC inhibitor EN4. These ligands were conjugated to cereblon (CRBN) or von Hippel–Lindau (VHL) E3 ligase recruiters using different linker architectures and connection sites. The resulting PROTACs were synthesized in high purity and characterized analytically. Cellular evaluation in HEK293T, Panc-1 and HCT-116 cancer cells revealed only moderate reductions in cell viability. Unfortunately, none of the synthesized PROTACs showed detectable MYC degradation at biologically relevant concentrations. Testing the stability of the PROTACs in microsomes showed rapid degradation, which may be a reason for the observed inactivity in cells. These results underscore the significant challenges associated with the targeted protein degradation of intrinsically disordered transcription factors such as MYC. Further studies are necessary to identify additional causes for the lack of MYC degradation and to optimize the chemical structures accordingly.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Institute of Pharmacy, Martin-Luther-University of Halle-Wittenberg, 06120 Halle (Saale), Germany.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, Egypt.
- Department of Molecular Medicine, Faculty of Medicine, Martin-Luther University Halle-Wittenberg, 06120 Halle (Saale), Germany.
- Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt.
ORCID-Profile: Abdallah M Alfayomy, Matthias Schmidt, Ali Fouad, Mohamed Ayman El-Zahabi, Stefan Hüttelmaier, Wolfgang Sippl
Förderung
- German Research Foundation DFG
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Alfayomy, A. M., Hagemann, S., Schmidt, M., Fouad, A., El-Zahabi, M. A., Hüttelmaier, S., & Sippl, W. (2026). Insights into the Design of MYC-Targeting Proteolysis Targeting Chimeras (PROTACs). Molecules. https://doi.org/10.3390/molecules31061011
Vancouver
Alfayomy AM, Hagemann S, Schmidt M, Fouad A, El-Zahabi MA, Hüttelmaier S, et al. Insights into the Design of MYC-Targeting Proteolysis Targeting Chimeras (PROTACs). Molecules. 2026. doi:10.3390/molecules31061011
BibTeX
@article{Alfayomy2026,
author = {Alfayomy, Abdallah M and Hagemann, Sven and Schmidt, Matthias and Fouad, Ali and El-Zahabi, Mohamed Ayman and Hüttelmaier, Stefan and Sippl, Wolfgang},
title = {Insights into the Design of MYC-Targeting Proteolysis Targeting Chimeras (PROTACs)},
journal = {Molecules},
year = {2026},
doi = {10.3390/molecules31061011}
}
EUVIMED